A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis

European Heart Journal

Volumn 36, Issue 18, 2015, Pages 1098-1105

  Sayed, Rabya H ^a   Rogers, Dominic ^b   Khan, Fakhar ^b   Wechalekar, Ashutosh D ^a   Lachmann, Helen J ^a   Fontana, Marianna ^a   Mahmood, Shameem ^a   Sachchithanantham, Sajitha ^a   Patel, Ketna ^a   Hawkins, Philip N ^a   Whelan, Carol J ^a,b   Gillmore, Julian D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Amyloidosis; Bradycardia; Cardiomyopathy; Implantable loop recorder

Indexed keywords

AMIODARONE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLECAINIDE; FUROSEMIDE; SPIRONOLACTONE; ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLETE HEART BLOCK; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTRIC ACTIVITY; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIAC MONITOR; MALE; PRESYNCOPE; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM; AMYLOIDOSIS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY; COMPLICATION; DEVICES; ELECTROCARDIOGRAPHY; ELECTRODE IMPLANT; HEART ARREST; INFORMATION PROCESSING; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; AMYLOIDOSIS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; DATA COLLECTION; ELECTROCARDIOGRAPHY, AMBULATORY; ELECTRODES, IMPLANTED; FEMALE; HEART ARREST; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84929612506     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu506     Document Type: Article

References (28)

1. Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223-241.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
3. Dispenzieri A, Gertz M, Kyle R, Lacy M, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757.
4. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses.NEngl J Med 1997;337: 898-909.
5. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112:2047-2060.
6. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-193.
7. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420-3427.
8. Dubrey SW, Cha K, Skinner M, LaValleyM, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74-82.
9. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-2445.
10. Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, Garini P, Merlini G. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001;24:1228-1233.
11. Lin G, Dispenzieri A, Brady PA. Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 2010;31:1538.
12. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A. Prophylactic implantation of cardioverterdefibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5:235-240.
13. Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984;3:107-113.
14. Wechalekar AD, Hawkins PN. AL amyloidosis: new drugs and tests, but old challenges. Oncology (Williston Park, NY) 2012;26:161-162, 4.
15. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart Rhythm 2008;5:e1-62.
16. Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, Schrier SL, Witteles RM. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 2014;11:158-162.
17. LinG,Dispenzieri A, Kyle R, Grogan M, Brady PA. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 2013;24:793-798.
18. Raviele A, Giada F, Bergfeldt L, Blanc JJ, Blomstrom-Lundqvist C, Mont L, Morgan JM, Raatikainen MJ, Steinbeck G, Viskin S, Kirchhof P, Braunschweig F, Borggrefe M, Hocini M, Della Bella P, Shah DC. Management of patients with palpitations: A position paper from the European Heart Rhythm Association. Europace 2011;13: 920-934.
19. Johnson RL,Averill KH, Lamb LE. Electrocardiographic findings in 67,375 asymptomatic subjects. VII. Atrioventricular block. Am J Cardiol 1960;6:153-177.
20. Rosenbaum MB, Elizari MV, Lazzari JO. The Hemiblocks. Oldsmar, FL: Tampa Tracings; 1970.
21. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133.
22. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, Galderisi M, Marwick T, Nagueh SF, Sengupta PP, Sicari R, Smiseth OA, Smulevitz B, Takeuchi M, Thomas JD, Vannan M, Voigt JU, Zamorano JL. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr 2011;12: 167-205.
23. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-328.
24. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJ Med 1998;91:141-157.
25. Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 1997;80:1242-1245.
26. Lachmann H, Gillmore JD. Renal amyloidosis. Br J Hosp Med 2010;71:83-86.
27. Algalarrondo V, Dinanian S, Juin C, Chemla D, Bennani SL, Sebag C, Plante V, Le Guludec D, Samuel D, Adams D, Slama MS. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm 2012;9:1069-1075.
28. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-995.